{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:43:28Z","timestamp":1790419408487,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00198-025-07621-y","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T13:12:23Z","timestamp":1754053943000},"page":"1701-1709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A cost-saving analysis of pharmacologic management in osteoporotic fracture prevention among postmenopausal women"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3498-8207","authenticated-orcid":false,"given":"Joshua","family":"Cassinat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vonda","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"issue":"12","key":"7621_CR1","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1007\/s00198-023-06881-w","volume":"34","author":"A Barcelos","year":"2023","unstructured":"Barcelos A, Gon\u00e7alves J, Mateus C, Canh\u00e3o H, Rodrigues AM (2023) Costs of incident non-hip osteoporosis-related fractures in postmenopausal women from a payer perspective. Osteoporosis International. 34(12):2111\u20132119. https:\/\/doi.org\/10.1007\/s00198-023-06881-w","journal-title":"Osteoporosis International."},{"key":"7621_CR2","doi-asserted-by":"publisher","first-page":"882241","DOI":"10.3389\/fendo.2022.882241","volume":"13","author":"Y Shen","year":"2022","unstructured":"Shen Y, Huang X, Wu J et al (2022) The global burden of osteoporosis, low bone mass, and its related fracture in 204 countries and territories, 1990\u20132019. Frontiers in Endocrinology 13:882241. https:\/\/doi.org\/10.3389\/fendo.2022.882241","journal-title":"Frontiers in Endocrinology"},{"key":"7621_CR3","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.14671","volume":"11","author":"J Deutschbein","year":"2023","unstructured":"Deutschbein J, Lindner T, M\u00f6ckel M et al (2023) Health-related quality of life and associated factors after hip fracture. Results from a six-month prospective cohort study. PeerJ. 11:e14671","journal-title":"PeerJ."},{"issue":"4","key":"7621_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/GME.0000000000000519","volume":"23","author":"L Zhu","year":"2016","unstructured":"Zhu L, Jiang X, Sun Y, Shu W (2016) Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause 23(4):461\u2013470","journal-title":"Menopause"},{"issue":"13","key":"7621_CR5","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","volume":"310","author":"JE Manson","year":"2013","unstructured":"Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women\u2019s health initiative randomized trials. JAMA 310(13):1353. https:\/\/doi.org\/10.1001\/jama.2013.278040","journal-title":"JAMA"},{"key":"7621_CR6","unstructured":"CMS.\u202fMedicare Part D Drug Spending Dashboard.\u202fAvailable at https:\/\/data.cms.gov\/tools\/medicare-part-d-drug-spending-dashboard. Accessed July\u202f30,\u202f2024."},{"issue":"6","key":"7621_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00198-020-05769-3","volume":"32","author":"O Tran","year":"2021","unstructured":"Tran O, Silverman S, Xu X et al (2021) Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women. Osteoporosis International 32(6):1195\u20131205. https:\/\/doi.org\/10.1007\/s00198-020-05769-3","journal-title":"Osteoporosis International"},{"key":"7621_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldaa005","author":"MA Clynes","year":"2020","unstructured":"Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C (2020) The epidemiology of osteoporosis. British Medical Bulletin. https:\/\/doi.org\/10.1093\/bmb\/ldaa005","journal-title":"British Medical Bulletin"},{"key":"7621_CR9","doi-asserted-by":"crossref","unstructured":"Cauley JA, Robbins J, Chen Z et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial. JAMA 13:1729\u201338","DOI":"10.1001\/jama.290.13.1729"},{"key":"7621_CR10","doi-asserted-by":"crossref","unstructured":"Mosekilde L, Beck-Nielsen H, S\u00f8rensen OH, et al (2000) Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas 3:181\u2013193","DOI":"10.1016\/S0378-5122(00)00158-4"},{"key":"7621_CR11","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.psyneuen.2009.02.009","volume":"7","author":"MC Tierney","year":"2009","unstructured":"Tierney MC, Oh P, Moineddin R et al (2009) A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. Psychoneuroendocrinology 7:1065\u201310674","journal-title":"Psychoneuroendocrinology"},{"key":"7621_CR12","doi-asserted-by":"crossref","unstructured":"Cauley JA, Black DM, Barrett-Connor E et al (2001) Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen\/Progestin Replacement Study (HERS). Am J Med 110(6):442-450","DOI":"10.1016\/S0002-9343(01)00647-7"},{"issue":"7613","key":"7621_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/bmj.39266.425069.ad","volume":"335","author":"MR Vickers","year":"2007","unstructured":"Vickers MR, Maclennan AH, Lawton B et al (2007) Main morbidities recorded in the women\u2019s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 335(7613):239. https:\/\/doi.org\/10.1136\/bmj.39266.425069.ad","journal-title":"BMJ"},{"key":"7621_CR14","doi-asserted-by":"crossref","unstructured":"Cherry N, Gilmour K, Hannaford P et al (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 360(9350):2001\u20138","DOI":"10.1016\/S0140-6736(02)12001-0"},{"key":"7621_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0378-5122(98)00085-1","volume":"1","author":"MH Komulainen","year":"1998","unstructured":"Komulainen MH, Kr\u00f6ger H, Tuppurainen MT et al (1998) HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas. 1:45\u201354","journal-title":"Maturitas."},{"key":"7621_CR16","doi-asserted-by":"crossref","unstructured":"Ravn P, Bidstrup M, Wasnich RD et al (1999) Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 12:935\u201342","DOI":"10.7326\/0003-4819-131-12-199912210-00005"},{"issue":"22","key":"7621_CR17","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1001\/archinte.157.22.2609","volume":"157","author":"HK Genant","year":"1997","unstructured":"Genant HK, Lucas J, Weiss S (1997) Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab\/Osteoporosis Study Group. Arch Intern Med 157(22):2609\u20132615. https:\/\/doi.org\/10.1001\/archinte.157.22.2609","journal-title":"Arch Intern Med"},{"issue":"5","key":"7621_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/00042192-200209000-00007","volume":"9","author":"M Notelovitz","year":"2002","unstructured":"Notelovitz M, John VA, Good WR (2002) Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women. Menopause 9(5):343\u2013353. https:\/\/doi.org\/10.1097\/00042192-200209000-00007","journal-title":"Menopause"},{"key":"7621_CR19","doi-asserted-by":"crossref","unstructured":"Veerus P, Hovi SL, Fischer K, Rahu M, Hakama M, Hemminki E (2006) Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas 2:162\u201373","DOI":"10.1016\/j.maturitas.2006.01.012"},{"issue":"18","key":"7621_CR20","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/nejm199005033221803","volume":"322","author":"T Storm","year":"1990","unstructured":"Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New England Journal of Medicine 322(18):1265\u20131271. https:\/\/doi.org\/10.1056\/nejm199005033221803","journal-title":"New England Journal of Medicine"},{"key":"7621_CR21","doi-asserted-by":"publisher","unstructured":"Liberman UA, Weiss SR, Br\u00f6ll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333(22):1437\u20131444. https:\/\/doi.org\/10.1056\/nejm199511303332201","DOI":"10.1056\/nejm199511303332201"},{"key":"7621_CR22","doi-asserted-by":"crossref","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 9041:1535\u20131541","DOI":"10.1016\/S0140-6736(96)07088-2"},{"key":"7621_CR23","first-page":"2077 \u201382","volume":"24","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 24:2077\u201382","journal-title":"JAMA"},{"issue":"8","key":"7621_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1056\/nejm199802193380801","volume":"338","author":"D Hosking","year":"1998","unstructured":"Hosking D, Chilvers CED, Christiansen C et al (1998) Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 338(8):485\u2013492. https:\/\/doi.org\/10.1056\/nejm199802193380801","journal-title":"N Engl J Med"},{"key":"7621_CR25","doi-asserted-by":"crossref","unstructured":"Harris ST, Watts NB, Genant HK et al 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 14:1344\u201352","DOI":"10.1001\/jama.282.14.1344"},{"issue":"1","key":"7621_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J-Y Reginster","year":"2000","unstructured":"Reginster J-Y, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis International. 11(1):83\u201391. https:\/\/doi.org\/10.1007\/s001980050010","journal-title":"Osteoporosis International."},{"issue":"5","key":"7621_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/nejm200102013440503","volume":"344","author":"MR Mcclung","year":"2001","unstructured":"Mcclung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. New England Journal of Medicine. 344(5):333\u2013340. https:\/\/doi.org\/10.1056\/nejm200102013440503","journal-title":"New England Journal of Medicine."},{"issue":"5","key":"7621_CR28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1359\/jbmr.040116","volume":"19","author":"E Mccloskey","year":"2004","unstructured":"Mccloskey E, Selby P, Davies M et al (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. Journal of Bone and Mineral Research 19(5):728\u2013736. https:\/\/doi.org\/10.1359\/jbmr.040116","journal-title":"Journal of Bone and Mineral Research"},{"issue":"8","key":"7621_CR29","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/jbmr.040325","volume":"19","author":"CH Chesnut 3rd","year":"2004","unstructured":"Chesnut CH 3rd, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19(8):1241\u20131249. https:\/\/doi.org\/10.1359\/jbmr.040325","journal-title":"J Bone Miner Res"},{"issue":"1","key":"7621_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1359\/jbmr.061008","volume":"22","author":"EV Mccloskey","year":"2007","unstructured":"Mccloskey EV, Beneton M, Charlesworth D et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. Journal of Bone and Mineral Research 22(1):135\u2013141. https:\/\/doi.org\/10.1359\/jbmr.061008","journal-title":"Journal of Bone and Mineral Research"},{"key":"7621_CR31","doi-asserted-by":"publisher","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799\u20131809. https:\/\/doi.org\/10.1056\/nejmoa074941","DOI":"10.1056\/nejmoa074941"},{"issue":"8","key":"7621_CR32","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00198-008-0816-7","volume":"20","author":"T Matsumoto","year":"2009","unstructured":"Matsumoto T, Hagino H, Shiraki M et al (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporosis International 20(8):1429\u20131437. https:\/\/doi.org\/10.1007\/s00198-008-0816-7","journal-title":"Osteoporosis International"},{"issue":"6","key":"7621_CR33","first-page":"1381","volume":"29","author":"M Chao","year":"2013","unstructured":"Chao M, Hua Q, Yingfeng Z et al (2013) Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women. Pak J Med Sci 29(6):1381\u20131384","journal-title":"Pak J Med Sci"},{"issue":"3","key":"7621_CR34","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/0300060513480917","volume":"41","author":"H Bai","year":"2013","unstructured":"Bai H, Jing D, Guo A, Yin S (2013) Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women. J Int Med Res 41(3):697\u2013704. https:\/\/doi.org\/10.1177\/0300060513480917","journal-title":"J Int Med Res"},{"issue":"5","key":"7621_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40266-016-0344-7","volume":"33","author":"EMM Van De Glind","year":"2016","unstructured":"Van De Glind EMM, Willems HC, Eslami S et al (2016) Estimating the time to benefit for preventive drugs with the statistical process control method: an example with alendronate. Drugs and Aging. 33(5):347\u2013353. https:\/\/doi.org\/10.1007\/s40266-016-0344-7","journal-title":"Drugs and Aging."},{"issue":"16","key":"7621_CR36","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/nejmoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. New England Journal of Medicine 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/nejmoa1607948","journal-title":"New England Journal of Medicine"},{"key":"7621_CR37","doi-asserted-by":"crossref","unstructured":"Adami S, Libanati C, Boonen S et al (2012) Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am 23:2113\u20132119","DOI":"10.2106\/JBJS.K.00774"},{"issue":"8","key":"7621_CR38","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/nejmoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, Mcclung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765. https:\/\/doi.org\/10.1056\/nejmoa0809493","journal-title":"N Engl J Med"},{"key":"7621_CR39","doi-asserted-by":"crossref","unstructured":"Van Oostwaard M. Osteoporosis and the nature of fragility fracture: an overview. Perspectives in Nursing Management and Care for Older Adults. Springer International Publishing; 2018:1\u201313.","DOI":"10.1007\/978-3-319-76681-2_1"},{"issue":"10","key":"7621_CR40","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL et al (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33(10):2049\u20132102","journal-title":"Osteoporos Int"},{"issue":"12","key":"7621_CR41","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s11606-015-3349-8","volume":"30","author":"ALD Amarnath","year":"2015","unstructured":"Amarnath ALD, Franks P, Robbins JA, Xing G, Fenton JJ (2015) Underuse and overuse of osteoporosis screening in a regional health system: a retrospective cohort study. Journal of General Internal Medicine 30(12):1733\u20131740. https:\/\/doi.org\/10.1007\/s11606-015-3349-8","journal-title":"Journal of General Internal Medicine"},{"key":"7621_CR42","doi-asserted-by":"publisher","unstructured":"Papaioannou A, Giangregorio L, Kvern B, Boulos P, Ioannidis G, Adachi J (2004) The osteoporosis care gap in Canada. BMC Musculoskeletal Disorders 5(1). https:\/\/doi.org\/10.1186\/1471-2474-5-11","DOI":"10.1186\/1471-2474-5-11"},{"key":"7621_CR43","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.2147\/ppa.s430203","volume":"17","author":"K Barber","year":"2023","unstructured":"Barber K, Charles A (2023) Barriers to accessing effective treatment and support for menopausal symptoms: a qualitative study capturing the behaviours, beliefs and experiences of key stakeholders. Patient Preference and Adherence 17:2971\u20132980. https:\/\/doi.org\/10.2147\/ppa.s430203","journal-title":"Patient Preference and Adherence"},{"issue":"5","key":"7621_CR44","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/jep.12389","volume":"21","author":"I Hernandez","year":"2015","unstructured":"Hernandez I, Zhang Y (2015) Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis. Journal of Evaluation in Clinical Practice. 21(5):840\u2013847. https:\/\/doi.org\/10.1111\/jep.12389","journal-title":"Journal of Evaluation in Clinical Practice."},{"issue":"9","key":"7621_CR45","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s00198-015-3154-6","volume":"26","author":"A Od\u00e9n","year":"2015","unstructured":"Od\u00e9n A, Mccloskey EV, Kanis JA, Harvey NC, Johansson H (2015) Burden of high fracture probability worldwide: secular increases 2010\u20132040. Osteoporosis International 26(9):2243\u20132248. https:\/\/doi.org\/10.1007\/s00198-015-3154-6","journal-title":"Osteoporosis International"},{"issue":"3","key":"7621_CR46","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. Journal of Bone and Mineral Research. 22(3):465\u2013475. https:\/\/doi.org\/10.1359\/jbmr.061113","journal-title":"Journal of Bone and Mineral Research."},{"issue":"9","key":"7621_CR47","doi-asserted-by":"publisher","first-page":"e10192","DOI":"10.1002\/jbm4.10192","volume":"3","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Ortendahl JD, Vanderpuye-Orgle J et al (2019) Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States. JBMR Plus. 3(9):e10192. https:\/\/doi.org\/10.1002\/jbm4.10192","journal-title":"JBMR Plus."},{"issue":"1","key":"7621_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11657-022-01117-6","volume":"17","author":"P Chotiyarnwong","year":"2022","unstructured":"Chotiyarnwong P, Mccloskey EV, Harvey NC et al (2022) Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology\/Quality of Life Working Group. Archives of Osteoporosis 17(1):87. https:\/\/doi.org\/10.1007\/s11657-022-01117-6","journal-title":"Archives of Osteoporosis"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07621-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07621-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07621-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:04:27Z","timestamp":1758747867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07621-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7621"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07621-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}